Abstract Venous thromboembolism is a serious but potentially preventable condition. However, morbidity and mortality occur due to lack of thrombo-prophylaxis. Obstetrics and gynecology patients are at risk for developing venous thromboembolism. To improve adherence to thromboprophylaxis in this patient population, we developed a smart phone clinical decision support system designed to assess risk score and recommend thromboprophylaxis. Clinical data were collected by review of electronic medical charts. The risk score and thromboprophylaxis recommendations were calculated for each patient by clinical decision support system and by an expert hematologist and results were compared for correlation. We hypothesize that the system is a valid tool for risk assessment in obstetrics and gynecology patients. A total of 188 female patients admitted at King Abdulaziz University Hospital between December 2015 and March 2016 were included. One hundred and sixteen were gynecology, and 72 were obstetric patients with a mean age of 40.7 (± 12.8). The risk score obtained by the system showed a strong correlation with that of the expert hematologist' s opinion (r = 83%). The clinical decision support system showed a good correlation for thromboprophylaxis decision as well. Accessibility and ease of use of clinical decision support system can improve the clinical outcome of hospitalized patients.
Introduction

V
enous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism is a preventable condition, yet considerable morbidity and mortality occur due to failure to provide prophylaxis to patients at risk [1] .
Mortality related to VTE is more than combined deaths from breast cancer, motor vehicle collisions and www.jkaumedsci.sa
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AIDS [2] . Available data show that hospital-acquired VTE can be prevented by early risk assessment and initiation of appropriate thromboprophylaxis [3] [4] [5] . However, patients are not always assessed for risk of VTE upon hospital admission, and thromboprophylaxis is vastly underutilized in the inpatient setting [6, 7] . Many protocols were designed for obstetrics and gynecology patient to prevent VTE. However, evidence has demonstrated that passive promulgation of guidelines and education alone are unlikely to improve VTE prophylaxis [4] . Venous thromboembolism risk assessment tools in hospitalized patients may be a useful and practical way to provide physicians with an evidence-based medicine algorithm for thromboprophylaxis and ultimately improve inpatient outcome [8, 9] . This pilot study is conducted to validate a smartphone application clinical decision support system (CDSS). We hypothesize that the VTE CDSS application is a valid tool for risk stratifi cation and recommendation of VTE thromboprophylaxis among hospitalized obstetrics and gynecology patients.
Participants and Methods
Inclusion Criteria
All patients admitted to the obstetrics and gynecology ward at King Abdulaziz University Hospital (KAUH) between the period of December 2015 and March 2016, were included.
Exclusion Criteria
Patients with a diagnosis of acute DVT or PE were excluded from the study as well as patients with known thrombophilia.
Methodology
All patients admitted to obstetrics and gynecology ward at KAUH between December 2015 and March 2016, were included in the analysis.
Data were collected by review of patients' electronic medical records.
The following variables were extracted: age, admission diagnosis, acute infections, cardiac or respiratory diseases, active malignancy, recent surgery, previous VTE, and history of hormonal therapy. In obstetric patients, additional risk factors included preeclampsia, hyperemesis and mode of delivery whether vaginal delivery, planned caesarean section (CS), or emergency CS. Clinical contraindications for pharmacological thromboprophylaxis and thromboprophylaxis received during the same admission, were collected.
Clinical Decision Support System Tool Development
We developed a smart phone CDSS which include risk assessment tool, heparin exclusion centre, dose adjustment option in case of renal impairment and recommendation for thromboprophylaxis. The risk assessment is based on Caprini risk assessment model (RAM) for surgical patients, Padua score for medical patients and the Royal College of Obstetrics and Gynecology risk assessment model (RCOG) score for pregnant women [10] [11] [12] .
A list of VTE risk factors were incorporated in the CDSS. A score of one was assigned for the following risk factors: Age > 35 years, body mass index (BMI) > 30, parity > 3, immobility for four days, varicose veins, systemic infections, pre-eclampsia, second or third trimester of pregnancy, hospital admission, multiple pregnancy, smoking and in vitro fertilization. Furthermore, a score of 1.5 was assigned for heart or lung disease, infl ammatory diseases, nephrotic syndrome, surgery, oestrogen related VTE with negative family history or thrombophilia. Finally, a score of 3 was assigned for history of anti-phospholipid syndrome, unprovoked VTE, oestrogen related VTE with positive family history or positive thrombophilia screen or patients with history of recurrent VTE [12] .
The CDSS also has a heparin exclusion centre which included the following criteria: active bleeding, hypersensitivity to heparins, heparin induced thrombocytopenia, recent intra ocular or intracranial surgery within the past three months, spinal tap within the past 24 hours, inherited or acquired coagulopathy, the use of oral anticoagulant, platelets less than 70 x 10 9 /L, oesophageal varices, active peptic ulcers, and intracranial aneurysm or angioma [1] .
Total score of equal to or more than four was identifi ed as high-risk score and is an indication for thromboprophylaxis. Venous thromboembolism risk score assessment by an independent expert hematologist was based on RCOG scoring system. The total risk score for VTE was calculated for each patient, both by using the smart phone CDSS and by an independent expert hematologist. Thromboprophylaxis decision generated by the smart phone CDSS was compared to that of the expert in terms of the indications for thromboprophylaxis whether thromboprophylaxis is indicated or not. Validity of the CDSS was tested by correlating the decision generated by CDSS to that of expert hematologist.
Statistical Methods
All the demographic data were entered into the predesigned proforma. Data was analysed using IBM SPSS Statistics for Windows, Version 20 (IBM Corp., Armonk, NY USA). Mean and standard deviation were calculated for quantitative variables like age and BMI. The correlation coeffi cient is a measure that determines the degree to which two variables' movements are associated. A positive corroboration, when r is greater than 0, signifi es that both variables move in the same direction. The closer the value of r is to +1, the stronger the linear relationship. The Pearson's correlation coeffi cient analysis was done between the recommendation in each patient between CDSS and the expert. The percent correlation coeffi cient was used for validation.
Results
One hundred and eighty-eight patients were included in the study. Of these, 116 (61%) were gynecology patients, and 72 (39%) were obstetric. Age ranged between 17 and 81 (mean age 40.7 ± 12.8). Body mass index ranged from 16-54 (Mean = 28.4 ± 7.0). (Table  1) . Sixty-seven percent of all patients were classifi ed as high risk for developing VTE according to CDSS as shown in Figure 1 .
Gynecology Patients
There were 116 (61%) patients with gynaecological diagnoses, with a mean age of 45.5 (± 13.5), and a mean BMI of 28.1 (± 6.8) ( Table 1) . Patients with a high score represented 54% (Fig. 1) . www.jkaumedsci.sa
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Obstetric Population
Seventy-two patients (38.3%) were admitted during pregnancy. The mean age for obstetric patient was 33.2 (± 6.24). Of these 18% where primigravidae, 30.5% were admitted during the fi rst trimester, 30.5% in the second trimester and 38.8% in the third trimester. The mean BMI was 28.9 (± 7.2). Patients with a high score represented 47% (Fig. 1) . The prevalence of risk factors for VTE among obstetrics and gynecology patients are shown in Table 2 .
Validation of Clinical Decision Support System
Correlation studies between expert opinion and CDSS regarding decision for thromboprophylaxis showed strong positive correlation in all patients; in gynecology and in obstetrics patients (r = 0.9, 0.94 and 0.81), respectively, using Pearson's correlation (Table 3) .
Discussion
The risk of VTE among hospitalized patients can be markedly reduced with proper thromboprophylaxis [1] . However, there is poor adherence to thromboprophylaxis guidelines among hospitalized patients [13] . Furthermore, women are more likely than men not to receive thromboprophylaxis [14] . Risk factors for VTE include advanced age, obesity, smoking and the use of oral contraceptive pills [15] [16] [17] [18] . Family history of VTE, inherited thrombophilia, recent surgery, and active malignancy are also major risk factors [19] . Table 3 . Correlation coeffi cient between clinical decision support system and expert opinion in all patients and in obstetrics and gynecology patients.
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Venous thromboembolism prevalence, risk factors and risk assessment models vary between obstetrics and gynecology patients.
The hypercoagulable status of pregnancy is a physiological method of adaptation to reduce risk of haemorrhage during and after delivery. Pregnant women are at higher risk of VTE compared to nonpregnant women. Clinically signifi cant VTE occurs in 1 of every 1000 pregnancy and 1 in 2000 deliveries and it is considered as one of the most common causes of maternal deaths [20] . The risk further increases to multiple folds in the third trimester and during hospitalization [21] . Treatment of VTE during pregnancy presents a signifi cant challenge to healthcare providers [22] . Moreover, guidelines on the management of VTE, are developed based on data in the non-pregnant patient and extrapolated to obstetric patients [23] . On the other hand, risk factors for VTE among gynaecological patients include; high BMI, diabetes mellitus, longer hospital stay and longer operative time [24] . Following gynaecologic surgery, the incidence of VTE secondary to lack of thromboprophylaxis is between 17-40% [25] . The risk of VTE is particularly high following surgery for gynaecological malignancies and hysterectomy [26] .
Despite the availability of RAM and guidelines for thromboprophylaxis, guidelines are generally underutilized [25] . Methods to improve adherence of thromboprophylaxis guidelines in the hospital include RAM tools whether as cards or in electronic form. Strategies for improvement of adherence to VTE prophylaxis such as laminated cards and educational training were not adequate to improve outcomes and reduce rates of VTE [4] . Risk stratifi cation in the absence of a RAM tool can be challenging [27] . Clinical decision support system is an appropriate and easily accessible method for improving qualitative health care. Kucher et al. [29] showed that when computer-generated alerts highlight risk factors, improvement in adherence to VTE prophylaxis was noted. Physicians have started using computer-alert program resulting in reduced rates of VTE in hospitalized patients at risk [29] . Furthermore, a systematic review summarizing trials of CDSS implementation concluded that CDSSs are eff ective at improving health care process measures across diverse settings, but evidence for clinical, economic, workload, and effi ciency outcomes remains sparse [30] . The review also concluded that CDSS systems with embedded algorithms have been used as an eff ective tool for prevention of VTE [30] . In addition, Haut et al. [31] showed that implementation of a CDSS signifi cantly improved compliance with VTE prophylaxis guidelines in hospitalized adult trauma patients. This improved compliance was associated with a signifi cant decrease in the rate of preventable VTE events. However, systematic testing of CDSS prior to release to general users is a critical aspect of high quality software design. Omission of this step may lead to potentially fatal condition of relying on a system with outputs of uncertain quality. Testing requires a great deal of eff ort and it requires attention to a large number of details.
In our study, we validated a locally developed smartphone CDSS for VTE risk stratifi cation using the widely accepted RAM which generate a thromboprophylaxis decision among hospitalized obstetrics and gynecology patients. The routine use of this tool in a hospital setting could advance physician knowledge, enable physicians to intervene early, assist in choosing the most eff ective method of thromboprophylaxis and improve patient outcomes. Moreover, in remote areas and in facilities with limited resources or lack of specialists, CDSS could be a useful tool.
Limitations
The study limitations include small sample size. Furthermore, only one hospital was included in the study and the CDSS needs to be validated outside of experienced academic centres. In addition, for meaningful validation multiple expert hematologists should be included. Finally, the study did not address the clinical and economic outcomes.
Considerations for Further Research
Future research should be undertaken to establish validity using a larger, more diverse sample size. Furthermore, longitudinal follow-up of assessed patients for verifi cation of our CDSS is required before it is introduced in routine clinical practice. In addition, post-implementation study should evaluate the eff ect of CDSS on physician compliance with evidence-based guidelines and on VTE outcomes in patient population.
Conclusion
Clinical decision support system has shown validity for risk stratifi cation of hospitalized obstetrics and gynecology patients, when compared to an expert 
